TR10: Dual-Action Antibodies
At Genentech, one of this year’s TR10 innovators, Germaine Fuh is developing a new variety of drug that can target more than one type of molecule, potentially reducing costs and simplifying treatment. We asked Fuh how it worked and what it might mean for patients.
At Genentech, one of this year’s TR10 innovators, Germaine Fuh is developing a new variety of drug that can target more than one type of molecule, potentially reducing costs and simplifying treatment. We asked Fuh how it worked and what it might mean for patients.
Deep Dive
Uncategorized
Our best illustrations of 2022
Our artists’ thought-provoking, playful creations bring our stories to life, often saying more with an image than words ever could.
How CRISPR is making farmed animals bigger, stronger, and healthier
These gene-edited fish, pigs, and other animals could soon be on the menu.
The Download: the Saudi sci-fi megacity, and sleeping babies’ brains
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. These exclusive satellite images show Saudi Arabia’s sci-fi megacity is well underway In early 2021, Crown Prince Mohammed bin Salman of Saudi Arabia announced The Line: a “civilizational revolution” that would house up…
10 Breakthrough Technologies 2023
Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.